Health Care Distributors

ETHK LABS INC.

ETHK LABS INC. released FY2025 9 Months earnings on March 27 (BJT), actual revenue HKD 2.222 B, actual EPS HKD 0.0246

ETHK LABS INC. released FY2025 Q3 earnings on March 27, 2026 (BJT) with actual revenue of HKD 847.79 M and EPS of HKD -0.0014

ETHK LABS INC. released FY2025 earnings on March 27 After-Market BJT, actual revenue HKD 3.083 B, actual EPS HKD 0.0236

ETHK LABS INC. released FY2025 Q4 earnings on March 27 After-Market (BJT), actual revenue HKD 862.42 M, actual EPS HKD -0.0014

ETHK LABS INC. FY2025 Annual Earnings Release on March 27, After-Market BJT

Carehouse Medical's Subsidiary Successfully Develops Bipartite Detection Solutions for Nipah Virus

Hu Jian Medical repurchased 470,000 shares for HKD 975,000

China Inspection Medical spends HKD 319,800 to repurchase 145,000 shares

Hu Jian Medical repurchased 1.187 million shares for HKD 7.7236 million

Hu Jian Medical Holding Limited repurchases 2,000 shares

Hu Jian Medical repurchases 2.027 million shares for HKD 12,472,400

Huajan Medical repurchased 430,000 shares

Huajan Medical Acquires Control of Chuangye Hikang for 500 Million Yuan

Hu Jian Medical repurchased 593,000 shares

Huajian Medical Acquires Controlling Stake in Chuangye Huis Kang

Hu Jian Medical repurchased 922,000 shares for HKD 5,998,500

Hu Jian Medical Holdings Announces and Executes Stock Repurchase

China Medical Inspection Repurchased 1.823 Million Shares for HKD 10.313 Million

Hu Jian Medical Begins Application for US Stablecoin License and Plans to Raise Funds to Increase US Dollar Reserves

IVD Medical Holding Limited Launches ivd.xyz Exchange and Develops IVDD Stablecoin

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

510660

589720

562600

01931

512010

513060

513120

512170

ETHK LABS INC. announced its full-year results for the year ended December last year, with a revenue of RMB 2.821 billion, a year-on-year decrease of 10.8%. The net profit was RMB 34.933 million, a year-on-year decrease of 86.6%; earnings per share were 2.16 cents. No dividend was declared

AASTOCKS

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI All Share Health Care Devices ETF

E Fund CSI 300 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Medical Service ETF

"Performance" ETHK LABS INC. last year net profit was 34.93 million RMB, down 86.6%, no dividend declared

159883

01515

ETHK LABS INC. issued a profit warning, expecting a profit of no more than RMB 42.2 million for the fiscal year 2025, compared to RMB 260 million recorded in the previous year. The decline in profit is mainly due to intensified competition in the in vitro diagnostics industry, resulting in a decrease in gross profit of RMB 185 million due to a decline in gross margin; administrative expenses increased by RMB 68 million, primarily due to increased professional fees related to the group's planned dual listing in the United States; and financing costs increased by approximately RMB 24.5 million

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

CR MEDICAL

"Profit Warning" CR MEDICAL's profit expected to decline, with a maximum profit of 42.2 million RMB last year

ETHK Labs Inc., a Hong Kong-listed in vitro diagnostics company, has warned of a significant profit drop for 2025, projecting earnings to fall to approximately RMB42.2 million from RMB260.4 million the previous year. The decline is attributed to increased competition, higher administrative costs related to U.S. listing preparations, and rising finance costs. The company is also pursuing a dual listing in the U.S. to enhance financing options. The latest analyst rating for its stock (HK:1931) is a Hold with a price target of HK$1.50.

Tip Ranks

ETHK Labs Warns of Sharp 2025 Profit Drop Amid Margin Squeeze and Listing Costs

ETHK Labs Inc. has reclassified its acquisition of B-Soft as a major transaction under Hong Kong listing rules after a review. The deal grants ETHK control over B-Soft’s board, necessitating the application of 100% of B-Soft’s assets for transaction-size tests. A reassessment revealed that the deal exceeds 25% but is below 100%, triggering stricter requirements. The board acknowledged prior non-compliance and plans to hold an extraordinary general meeting for shareholder approval to regularize the acquisition. The current analyst rating for IVD Medical Holding Limited (HK:1931) is a Hold with a price target of HK$1.50.

ETHK Labs Reclassifies B-Soft Deal as Major Transaction After Listing Rules Review

ETHK Labs Inc. has scheduled a board meeting for March 27, 2026, to review and approve its audited annual results for the financial year ending December 31, 2025. The board will also consider declaring a final dividend and address other corporate matters. The announcement confirms the current board composition, which includes three executive directors, two non-executive directors, and three independent non-executive directors. The latest analyst rating for IVD Medical Holding Limited (HK:1931) is a Hold with a price target of HK$1.50.

ETHK Labs Sets March 2026 Board Meeting to Approve 2025 Results

02545

01000

02513

06869

00772

01729

In the past hour, the Hong Kong stock market has shown a clear divergence, with the technology and healthcare sectors performing particularly well, attracting significant attention from funds. ZHONGGAN COMM's strong rise has boosted the activity of related telecom stocks, while BEIJING MEDIA has suffered a sharp decline due to weak market sentiment, indicating a rapid shift in fund preferences. Short-term enthusiasm has significantly increased among stocks with large price increases, with greater volatility, and market sentiment seems to be constantly changing, leading to adjustments in investors' risk appetite. In the past hour, the stock with the largest abnormal movement, ZHONGGAN COMM, led with a 20.00% increase, showing strong intraday performance and noticeable fund inflow, seemingly favored by the market. Its strong performance has not only attracted short-term funds but also invigorated the entire telecom sector, creating a high level of enthusiasm. Strong stocks: 1. KNOWLEDGE ATLAS: up 18.60%, with increased market attention on its technological innovations and significant fund inflow. 2. YOFC: up 15.53%, benefiting from a recovery in industry demand, with short-term funds actively involved. 3. ETHK LABS INC.: up 15.13%, with optimistic market expectations for its performance attracting substantial buying. 4. CHINA LIT: up 12.14%, with short-term enthusiasm continuing to rise as content consumption rebounds. 5. TIME INTERCON: up 10.33%, with technical breakthroughs triggering fund interest and impressive performance. Under pressure stocks: 1. BEIJING MEDIA: down 18.60%, with weak market sentiment and noticeable fund outflows, making the short-term outlook grim

HK Stock Alerts

ZHONGGAN COMM

BEIJING MEDIA

KNOWLEDGE ATLAS

YOFC

CHINA LIT

TIME INTERCON

Hong Kong Stock Movement Update: ZHONGGAN COMM surged 20%, BEIJING MEDIA fell 18.60%, short-term funds prefer technology stocks

ETHK LABS INC. rose 15.13%; China National Pharmaceutical Group fell 0.28%, with a transaction volume of HKD 41.69 million; Health 160 rose 1.79%, with a transaction volume of HKD 21.08 million; Shanghai Pharmaceuticals fell 0.42%, with a transaction volume of HKD 19.56 million; Baiyunshan fell 0.78%, with a market value of HKD 31.2 billion

Hong Kong Stock Movement: ETHK LABS INC. rises 15.13%, new Chief Scientist and AI trends boost stock price surge

ETHK Labs Inc. has announced its board composition, which includes three executive directors, two non-executive directors, and three independent non-executive directors. Independent non-executive director Zhang Jianlei will chair the audit, remuneration, and nomination committees, emphasizing independent oversight. The company is listed in Hong Kong under stock code 1931, with a current analyst rating of Hold and a price target of HK$1.50. The governance structure aligns with typical Hong Kong corporate governance standards, supporting regulatory compliance.

ETHK Labs Sets Out Board Composition and Committee Roles

ETHK LABS INC.(01931.HK)